En español In English Contact Us
 
 
 
 
 

eRenewal Exclusions

Accredo eRenewal Exclusions

Updated: 2016-02-12

THERAPY_CLASS

DRUG

Endocrinology

ANDROGEL

Oncology

ARANESP

Oncology

AZACITIDINE

Pulmonology/Transplant

BETHKIS

Oncology

BEXXAR

Oncology

BUSULFEX

Oncology

CAPRELSA

Oncology

CERUBIDINE

Oncology

CLADRIBINE

Oncology

CLOLAR

Oncology

COSMEGEN

Oncology

CRINONE

Oncology

DACTINOMYCIN

Oncology

DAUNORUBICIN HCL

Oncology

DAUNOXOME

Oncology

DECITABINE

Oncology

DEGARELIX

Oncology

DEPO-TESTOSTERONE

Oncology

DEXRAZOXANE

Oncology

DOCEFREZ

Oncology

ELITEK

Oncology

ELLENCE

Oncology

ELSPAR

Oncology

EMCYT

Oncology

EPOGEN

Oncology

ETHYOL

Oncology

ETOPOPHOS

Oncology

FLOXURIDINE

Oncology

FLUDARA

Oncology

HYDROXYCHLOROQUINE

Oncology

IDAMYCIN PFS

Oncology

IDARUBICIN HCL

Pulmonology/Transplant

ILUVIEN

Oncology

IRESSA

Pulmonology/Transplant

KALYDECO

Oncology

KEPIVANCE

Oncology

KEYTRUDA

Oncology

LEUSTATIN

Oncology

MARQIBO

Oncology

MELPHALAN HCL

Multiple Sclerosis

MIDAZOLAM

Oncology

MYLOTARG

Endocrinology

NATPARA

Oncology

NAVELBINE

Oncology

NEULASTA

Oncology

NEULASTA KIT

Oncology

NEUPOGEN

Oncology

NIPENT

Oncology

ONDANSETRON

Oncology

SYLVANT

Oncology

TEMODAR INJ

Oncology

TESTOPEL

Oncology

THIOGUANINE

Oncology

THIOTEPA

Oncology

TOPOTECAN HCL

Oncology

TOTECT

Oncology

TRETINOIN

Oncology

VANDETANIB

Oncology

VENOFER

Oncology

VUMON

Oncology

ZOFRAN

 

Share this page

CloseClose